Association between plasminogen activator inhibitor-1 gene polymorphisms and susceptibility to Parkinson’s disease in Chinese patients

2021 ◽  
Author(s):  
Qi Xu ◽  
Qilun Lai ◽  
Junjun Wang ◽  
Liying Zhuang ◽  
Lin Cheng ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Plasminogen Activator ◽  
Gene Polymorphisms ◽  
Plasminogen Activator Inhibitor ◽  
Chinese Patients ◽  
Plasminogen Activator Inhibitor 1 ◽  
Activator Inhibitor

scholarly journals Plasminogen activator inhibitor-1 gene polymorphism 4G/4G genotype and lupus nephritis in Chinese patients

2001 ◽  
Vol 59 (4) ◽  
pp. 1520-1528 ◽  
Author(s):  
Angela Yee Moon Wang ◽  
Peter Poon ◽  
Fernand Macmound Lai ◽  
Lymee Yu ◽  
Paul Cheung Lung Choi ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Gene Polymorphism ◽  
Plasminogen Activator ◽  
Plasminogen Activator Inhibitor ◽  
Chinese Patients ◽  
Plasminogen Activator Inhibitor 1 ◽  
Activator Inhibitor

scholarly journals Association between Five Common Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms and Colorectal Cancer Susceptibility

2020 ◽  
Vol 21 (12) ◽  
pp. 4334 ◽  
Author(s):  
Jisu Oh ◽  
Hui Jeong An ◽  
Jung Oh Kim ◽  
Hak Hoon Jun ◽  
Woo Ram Kim ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Plasminogen Activator ◽  
Gene Polymorphisms ◽  
Cancer Susceptibility ◽  
Plasminogen Activator Inhibitor ◽  
Cell Types ◽  
Plasminogen Activator Inhibitor 1 ◽  
Polymerase Chain ◽  
Activator Inhibitor ◽  
Pai 1

The plasminogen activator inhibitor-1 (PAI-1) is expressed in many cancer cell types and modulates cancer growth, invasion, and angiogenesis. The present study investigated the association between five PAI-1 gene polymorphisms and colorectal cancer (CRC) risk. Five PAI-1 polymorphisms (−844G > A [rs2227631], −675 4G > 5G [rs1799889], +43G > A [rs6092], +9785G > A [rs2227694], and +11053T > G [rs7242]) were genotyped using a polymerase chain reaction-restriction fragment length polymorphism assay in 459 CRC cases and 416 controls. Increased CRC risk was more frequently associated with PAI-1 −675 5G5G polymorphism than with 4G4G (adjusted odds ratio (AOR) = 1.556; 95% confidence interval (CI): 1.012–2.391; p = 0.04). In contrast, for the PAI-1 +11053 polymorphism, we found a lower risk of CRC with the GG genotype (AOR = 0.620; 95% CI: 0.413–0.932; p = 0.02) than with the TT genotype, as well as for recessive carriers (TT + TG vs. GG, AOR = 0.662; 95% CI: 0.469–0.933; p = 0.02). The +43AA genotype was associated with lower overall survival (OS) than the +43GG genotype. Our results suggest that the PAI-1 genotype plays a role in CRC risk. This is the first study to identify an association between five PAI-1 polymorphisms and CRC incidence worldwide.

Sign in / Sign up

Export Citation Format

Share Document